| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cardiology Unit, Department of Medicine, and Department of Neurobiology and Anatomy, University of Rochester Medical Center, Rochester, New York 14642
Chronic angiotensin-converting enzyme (ACE) inhibition has been shown to improve cardiac sympathetic nerve terminal function in heart failure. To determine whether similar effects could be produced by angiotensin II AT1 receptor blockade, we administered the ACE inhibitor quinapril, angiotensin II AT1 receptor blocker losartan, or both agents together, to rabbits with pacing-induced heart failure. Chronic rapid pacing produced left ventricular dilation and decline of fractional shortening, increased plasma norepinephrine (NE), and caused reductions of myocardial NE uptake activity, NE histofluorescence profile, and tyrosine hydroxylase immunostained profile. Administration of quinapril or losartan retarded the progression of left ventricular dysfunction and attenuated cardiac sympathetic nerve terminal abnormalities in heart failure. Quinapril and losartan together produced greater effects than either agent alone. The effect of renin-angiotensin system inhibition on improvement of left ventricular function and remodeling, however, was not sustained. Our results suggest that the effects of ACE inhibitors are mediated via the reduction of angiotensin II and that angiotensin II plays a pivotal role in modulating cardiac sympathetic nerve terminal function during development of heart failure. The combined effect of ACE inhibition and angiotensin II AT1 receptor blockade on cardiac sympathetic nerve terminal dysfunction may contribute to the beneficial effects on cardiac function in heart failure.
noradrenergic nerve endings; norepinephrine; tyrosine hydroxylase
This article has been cited by other articles:
|
|
 |
|
  D. J. Duncker and R. J. Bache Regulation of Coronary Blood Flow During Exercise Physiol Rev, July 1, 2008; 88(3): 1009 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Merkus, D. B. Haitsma, O. Sorop, F. Boomsma, V. J. de Beer, J. M. J. Lamers, P. D. Verdouw, and D. J. Duncker Coronary vasoconstrictor influence of angiotensin II is reduced in remodeled myocardium after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2082 - H2089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Munch, K. Rosport, A. Bultmann, C. Baumgartner, Z. Li, L. Laacke, and M. Ungerer Cardiac Overexpression of the Norepinephrine Transporter Uptake-1 Results in Marked Improvement of Heart Failure Circ. Res., October 28, 2005; 97(9): 928 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawai, F. Qin, J. Shite, W. Mao, S. Fukuoka, and C.-s. Liang Importance of antioxidant and antiapoptotic effects of {beta}-receptor blockers in heart failure therapy Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1003 - H1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Raasch, P. Dominiak, A. Ziegler, and A. Dendorfer Reduction of Vascular Noradrenaline Sensitivity by AT1 Antagonists Depends on Functional Sympathetic Innervation Hypertension, September 1, 2004; 44(3): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nap, C. N. Belterman, M.-J. Mathy, J. C Balt, M. Pfaffendorf, and P. A van Zwieten Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 220 - 227. [Abstract] [PDF]
|
|
|
|
|
|
R. Schulz, S. Aker, S. Belosjorow, I. Konietzka, U. Rauen, and G. Heusch Stress kinase phosphorylation is increased in pacing-induced heart failure in rabbits Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2084 - H2090. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
